Mitochondrial genome editing and regulation

Patent metadata

Field	Value
Publication number	US-11208652-B2
Application number	US-201716075247-A
Country	US
Kind code	B2
Filing date	Feb 2, 2017
Priority date	Feb 4, 2016
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

Methods and compositions of altering mitochondrial DNA of a eukaryotic cell are provided using one or more of a mitochondrial specific adeno-associated virus to deliver one or more nucleic acids encoding CRISPR system including a Cas9 protein or its nuclease inactive variant and a guide RNA into a mitochondria for expression within the mitochondria. The Cas9 system can cut, nick or regulate a target mitochondrial nucleic acid.

First claim

What is claimed is:

1. A method of altering mitochondrial DNA of a eukaryotic cell comprising
providing to the eukaryotic cell a first mito-specific adeno-associated virus vector including a first nucleic acid sequence encoding a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence and a mitochondrial specific promoter and mitochondrial specific start and stop codons,
providing to the eukaryotic cell a second mito-specific adeno-associated virus vector including a second nucleic acid sequence encoding a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner and a mitochondrial specific promoter and mitochondrial specific start and stop codons,
wherein the first vector delivers the first nucleic acid sequence into the mitochondria of the eukaryotic cell, wherein the first nucleic acid sequence is expressed,
wherein the second vector delivers the second nucleic acid sequence into the mitochondria of the eukaryotic cell, wherein the second nucleic acid sequence is expressed,
wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner.

2. The method of claim 1 further including the step of providing a donor sequence into the mitochondria and wherein the donor sequence is inserted into the mitochondrial DNA.

3. The method of claim 2 wherein the donor nucleic acid sequence and the gRNA are connected.

4. The method of claim 1 wherein the first vector includes a third nucleic acid sequence encoding a donor nucleic acid sequence.

5. The method of claim 1 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.

6. The method or claim 1 wherein the eukaryotic cell is a human cell.

7. The method of claim 1 wherein a plurality of guide RNAs are provided into the mitochondria that are complementary to different target mitochondrial nucleic acid sequences and the Cas9 enzyme cleaves the different target mitochondrial nucleic acid sequences in a site specific manner.

Assignees

• Harvard College

Inventors

• Church George M
• Yang Luhan
• Monroe Margo R

Classifications

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title